These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22972870)

  • 1. Tigecycline and overall mortality.
    Yahav D; Lador A; Paul M; Leibovici L
    Clin Infect Dis; 2012 Dec; 55(12):1739. PubMed ID: 22972870
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-level data provide additional insight for tigecycline all-cause mortality meta-analysis.
    McGovern PC; Quintana A
    Clin Infect Dis; 2012 Dec; 55(12):1739-40; author reply 1740-1. PubMed ID: 22972861
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.
    Powers JH
    Clin Infect Dis; 2012 Jun; 54(12):1710-3. PubMed ID: 22467671
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute necrotizing pancreatitis related to tigecycline.
    Mascarello M; Papa G; Arnez ZM; Luzzati R
    J Antimicrob Chemother; 2012 May; 67(5):1296-7. PubMed ID: 22279181
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 6. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates.
    Martín-Gandul C; García-Cabrera E; Castillo-Ojeda E; Jiménez-Mejías ME
    J Antimicrob Chemother; 2012 Apr; 67(4):1048-9. PubMed ID: 22207597
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections.
    Routsi C; Kokkoris S; Douka E; Ekonomidou F; Karaiskos I; Giamarellou H
    Int J Antimicrob Agents; 2015 Jan; 45(1):90-3. PubMed ID: 25241261
    [No Abstract]   [Full Text] [Related]  

  • 8. Extreme alkaline phosphatase elevation associated with tigecycline.
    Bonilla MF; Avery RK; Rehm SJ; Neuner EA; Isada CM; van Duin D
    J Antimicrob Chemother; 2011 Apr; 66(4):952-3. PubMed ID: 21393193
    [No Abstract]   [Full Text] [Related]  

  • 9. True incidence of tigecycline-induced pancreatitis: how many cases are we missing?
    Davido B; Shourick J; Makhloufi S; Dinh A; Salomon J
    J Antimicrob Chemother; 2016 Oct; 71(10):2994-5. PubMed ID: 27365188
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
    Rello J
    J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis.
    Verde PE; Curcio D
    Clin Infect Dis; 2012 Aug; 55(3):471-2. PubMed ID: 22511552
    [No Abstract]   [Full Text] [Related]  

  • 13. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
    Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of minocycline and tigecycline in a hamster model of leptospirosis.
    Tully CC; Hinkle MK; McCall S; Griffith ME; Murray CK; Hospenthal DR
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):366-9. PubMed ID: 22018938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia.
    Yılmaz Duran F; Yıldırım H; Şen EM
    Turk J Haematol; 2018 Mar; 35(1):83-84. PubMed ID: 29212626
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Scaglione F
    J Antimicrob Chemother; 2011 Dec; 66(12):2892-3; author reply 2895-6. PubMed ID: 21862475
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Curcio D; Verde PE
    J Antimicrob Chemother; 2011 Dec; 66(12):2893-5; author reply 2895-6. PubMed ID: 21921075
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 19. Tigecycline: benefits and risks.
    Cai Y; Wang R
    Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707
    [No Abstract]   [Full Text] [Related]  

  • 20. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database.
    Griffin AT; Harting JA; Christensen DM
    Diagn Microbiol Infect Dis; 2013 Nov; 77(3):273-7. PubMed ID: 24029432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.